A Phase 3 interventional study of Sodium zirconium cyclosilicate and Placebo in Hyperkalemia, sponsored by ZS Pharma, Inc.. Completed at 46 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-07.
Sponsored by ZS Pharma, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia — 3 open to participants now, 4 under way, none of them phase 3. sodium zirconium cyclosilicate · Hyperkalemia.
Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, this one is the 7th largest by enrollment, is one of 3 that started in 2014, is one of 12 in phase 3, and was the 1st registered.
134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.
Browse Hyperkalemia studies →3 of the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia are open now, in 2 countries. Recruiting first, the newest first:
AstraZeneca · Sites in India
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 18+
Qianfoshan Hospital
Ages 18–75
By country, each count listing its studies:
sodium zirconium cyclosilicate: first FDA approval 2018 (LOKELMA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 13 · Phase 4 6
First in 2014; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 258 is above the median of 88 across 103 interventional studies indexed under Hyperkalemia.
Median enrollment 120 across the 27 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under ZS Pharma, Inc., one of the names counted as AstraZeneca. Under that name alone:
ZS Pharma, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
39 studies in Hyperkalemia by AstraZeneca: 2 open now, 3 under way, 1 of them phase 3. Of 36 finished, 22 (61%) have results posted.
Among the 39 studies in Hyperkalemia by AstraZeneca, this one is the 9th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2014, is one of 13 in phase 3, and was the 4th registered.
AstraZeneca’s Hyperkalemia studies by the year they started, since 2011.
2 of the studies testing sodium zirconium cyclosilicate in Hyperkalemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06736184Qianfoshan HospitalThe Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients | 2026-12-31 |
| NCT07944378AstraZenecaA Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, from their registry updates:
Among AstraZeneca’s 39 in Hyperkalemia:
This tab as a report to print or save as PDF → With an account.
It is hypothesized that ZS is more effective than placebo control (alternative hypothesis) in maintaining mean double-blind randomized maintenance phase (DBRMP) Day 8-29 serum potassium levels (3.5 - 5.0 mmol/l, inclusive) among hyperkalemic subjects in whom normokalemia was established during the open-label acute phase versus no difference between each ZS dose (highest to lowest) versus placebo control (null hypothesis).
Approximately 275 subjects with hyperkalemia (two consecutive i-STAT potassium levels ≥ 5.1 mmol/l, taken 60 minutes apart at baseline) will be enrolled in the Open-label Acute Phase to provide 232 subjects in the Double Blind Randomized Maintenance Phase.
Initially all subjects will receive open-label ZS at a dose of 10g three times a day (tid) for 48 hours (AP). Subjects who achieve normokalemia (i-STAT potassium values between 3.5 to 5.0 mmol/l, inclusive) on the morning of Study Day 3 (after 6 doses of 10g ZS) will then, in a double-blind fashion, be randomized 4:4:4:7 to receive one of three doses of ZS (5g, 10g or 15g) or placebo control, qd for the following 28 days (DBRMP).
Safety and tolerability will be assessed on an ongoing basis by an Independent Data Monitoring Committee (iDMC). Each active dose group in the DBRMP will consist of 49 subjects and the placebo control group will consist of 85 subjects for a total of 232 subjects to detect a 0.6 effect size difference between each ZS dose (from highest to lowest) and placebo control; the 4:4:4:7 allocation optimizes the multiple comparisons to the placebo control for the DBRMP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sodium zirconium cyclosilicate 10 g three times daily for 48 hours (acute phase)
Drug: Sodium zirconium cyclosilicate
Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days.
Drug: Placebo
Sodium zirconium cyclosilicate (ZS) 5 g once daily for 28 days (maintenance phase)
Drug: Sodium zirconium cyclosilicate
Sodium zirconium cyclosilicate (ZS) 10 g once daily for 28 days (maintenance phase)
Drug: Sodium zirconium cyclosilicate
Sodium zirconium cyclosilicate (ZS) 15 g once daily for 28 days (maintenance phase)
Drug: Sodium zirconium cyclosilicate
Sodium zirconium cyclosilicate
Also known as: ZS; Microporous, Fractionated, Protonated Zirconium Silicate; Zirconium Silicate
Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
Also known as: Silicilate microcrystaline cellulose
Mean Serum Potassium Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT Population).
The least squares means (LSMeans) are dervied from a mixed effects model of serial log transformed S-K values between Days 8 and 29 with patients as a random effect and the following fixed effects terms: MP treatment group; AP baseline eGFR; AP and MP baseline S-K levels, age categories (\<55, 55-64, \>= 65 years); and binary indicators for RAAS inhibitors use, CKD, CHF, and DM. The LSmeans estimate obtained from the above model is back-transformed and presented as the lsmeans of all available S-K values during the Maintenance phase study Days 8 to 29.
Time frame: 22 Days; Maintenance Phase Days 8 - 29, inclusive.
The Number of Normokalemic Days Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT).
The number of normokalemic days during the Maintenance Phase Study Days 8 to 29 is calculated assuming that the interval between assessments is normokalemic only if both the beginning and end assessments for that time interval display normal S-K values (i.e. 3.5 - 5.0 mmol/L)
Time frame: 22 days; Maintenance Phase Day 8 - 29, inclusive.
Mean Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit .
Time frame: Acute Phase baseline to Maintenance Phase Study Day 2 to Day 29/Exit, inclusive.
Mean Percent Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit, Inclusive .
Time frame: Acute Phase baseline to Maintenance Phase Study Day 2 to Day 29/Exit, inclusive.
Mean Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit.
Time frame: Maintenance phase baseline to Maintenance Phase Study Day 29/Exit, inclusive.
Mean Percent Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit.
Time frame: Maintenance phase baseline to Maintenance Phase Study Day 29/Exit, inclusive.
Median Time to Hyperkalemia (S-K ≥ 5.1mmol/L)
Time frame: Maintenance Phase baseline to maintenance Phase Study Day 29/Exit.
Mean S-K Intra-subject Standard Deviation Calculated Among Subjects With ≥ 2 Values on or After Maintenance Phase Study Day 8
Time frame: 22 days; Maintenance Phase Day 8 - 29
Proportion of Subjects Who Remained Normokalemic During Maintenance Phase
Time frame: Maintenance Phase Study Days 1, 2, 5, 8, 12, 15, 19, 22, 26, 29, and 35, inclusive.
Median Time to Relapse in S-K Values
Median time to relapse in S-K values (return to original Acute Phase S-K baseline value)
Time frame: Maintenance phase Study Day 1 to Study Day 29/Exit.
Exponential Rate of Change in S-K Values During the Acute Phase at 24 Hours and 48 Hours of Study Drug Treatment.
Time frame: Acute Phase 24 hours and Acute Phase 48 hours.
Mean Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase.
Time frame: All measured time intervals post dose during the Acute Phase.
Mean Percent Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase.
Time frame: All measured time intervals post dose during the Acute Phase.
Proportion of Subjects Who Achieve Normokalemia During the Acute Phase at 24 and 48 Hours After Start of Dosing
Time frame: Through 48 hours acute phase
Median Time to Normalization (3.50-5.0 mmol/L) in S-K Levels in the 48 Hours of Initial Treatment
Time frame: Through 48 hours acute phase
Participants took part in the study at 44 sites in the United States, Australia, and South Africa from 31 March 2014 to 08 August 2014
| Milestone | ZS 10 g Three Times Daily (Acute Phase) | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) |
|---|---|---|---|---|---|
| Started | 258 | 0 | 0 | 0 | 0 |
| Completed | 251 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Hyperkalemia | 2 | 0 | 0 | 0 | 0 |
| Milestone | ZS 10 g Three Times Daily (Acute Phase) | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) |
|---|---|---|---|---|---|
| Started | 0 | 85 | 45 | 51 | 56 |
| Completed | 0 | 75 | 40 | 44 | 49 |
| Not completed | 0 | 10 | 5 | 7 | 7 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 3 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Sponsor's decision | 0 | 2 | 0 | 2 | 1 |
| Withdrew: Hypo- or hyperkalemia | 0 | 3 | 0 | 3 | 1 |
| Withdrew: Miscellaneous | 0 | 2 | 1 | 2 | 1 |
| Withdrew: Met ecg withdrawal criteria | 0 | 0 | 1 | 0 | 2 |
| Withdrew: Subject compliance | 0 | 1 | 0 | 0 | 0 |
The least squares means (LSMeans) are dervied from a mixed effects model of serial log transformed S-K values between Days 8 and 29 with patients as a random effect and the following fixed effects terms: MP treatment group; AP baseline eGFR; AP and MP baseline S-K levels, age categories (\<55, 55-64, \>= 65 years); and binary indicators for RAAS inhibitors use, CKD, CHF, and DM. The LSmeans estimate obtained from the above model is back-transformed and presented as the lsmeans of all available S-K values during the Maintenance phase study Days 8 to 29.
| mmol/L | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) |
|---|---|---|---|---|
| Mean Serum Potassium Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT Population). | 5.0603 (4.9646 to 5.1578) | 4.7544 (4.6350 to 4.8769) | 4.5081 (4.4005 to 4.6184) | 4.3742 (4.2754 to 4.4753) |
The number of normokalemic days during the Maintenance Phase Study Days 8 to 29 is calculated assuming that the interval between assessments is normokalemic only if both the beginning and end assessments for that time interval display normal S-K values (i.e. 3.5 - 5.0 mmol/L)
| Days | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) |
|---|---|---|---|---|
| The Number of Normokalemic Days Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT). | 7.4 ± 8.0 | 13.4 ± 7.57 | 13.9 ± 7.91 | 16.8 ± 6.99 |
| mmol/L | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) |
|---|---|---|---|---|
| AP Baseline S-K level | 5.55 ± 0.471 | 5.53 ± 0.357 | 5.58 ± 0.423 | 5.55 ± 0.331 |
| MP Study Day 2 Mean Change | -0.86 ± 0.508 | -1.03 ± 0.408 | -1.25 ± 0.471 | -1.12 ± 0.477 |
| MP Study Day 8 Mean Change | -0.49 ± 0.549 | -0.72 ± 0.552 | -1.09 ± 0.629 | -1.20 ± 0.592 |
| MP Study Day 12 Mean Change | -0.41 ± 0.508 | -0.75 ± 0.516 | -1.11 ± 0.663 | -1.20 ± 0.665 |
| MP Study Day 15 Mean Change | -0.48 ± 0.612 | -0.77 ± 0.492 | -1.11 ± 0.652 | -1.19 ± 0.627 |
| MP Study Day 19 Mean Change | -0.45 ± 0.549 | -0.79 ± 0.520 | -1.04 ± 0.581 | -1.07 ± 0.575 |
| MP Study Day 22 Mean Change | -0.45 ± 0.578 | -0.71 ± 0.543 | -0.93 ± 0.653 | -1.05 ± 0.586 |
| MP Study Day 26 Mean Change | -0.43 ± 0.552 | -0.65 ± 0.448 | -0.87 ± 0.697 | -1.03 ± 0.597 |
| MP Study Day 29 Mean Change | -0.47 ± 0.499 | -0.69 ± 0.500 | -1.08 ± 0.704 | -1.12 ± 0.571 |
| MP Study Day 29/Exit Mean Change | -0.44 ± 0.515 | -0.77 ± 0.559 | -1.10 ± 0.813 | -1.19 ± 0.659 |
| Percent Change | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) |
|---|---|---|---|---|
| MP Study Day 2 Percent Change | -15.11 ± 8.154 | -18.53 ± 6.941 | -22.19 ± 7.897 | -20.04 ± 7.959 |
| MP Study Day 8 Percent Change | -8.45 ± 9.492 | -12.84 ± 9.700 | -19.16 ± 10.708 | -21.29 ± 10.135 |
| MP Study Day 12 Percent Change | -7.22 ± 8.967 | -13.36 ± 8.949 | -19.45 ± 11.072 | -21.22 ± 11.368 |
| MP Study Day 15 Percent Change | -8.28 ± 10.739 | -13.73 ± 8.485 | -19.33 ± 10.884 | -21.19 ± 10.675 |
| MP Study Day 19 Percent Change | -7.87 ± 9.554 | -14.08 ± 8.822 | -18.29 ± 9.707 | -19.10 ± 9.957 |
| MP Study Day 22 Percent Change | -7.74 ± 9.992 | -12.65 ± 9.591 | -16.25 ± 11.292 | -18.65 ± 10.034 |
| MP Study Day 26 Percent Change | -7.54 ± 9.386 | -11.83 ± 8.025 | -15.18 ± 11.988 | -18.28 ± 10.271 |
| MP Study Day 29 Percent Change | -8.23 ± 8.586 | -12.49 ± 8.770 | -18.83 ± 11.951 | -19.80 ± 9.503 |
| MP Study Day 29/Exit Percent Change | -7.68 ± 8.940 | -13.85 ± 9.568 | -19.28 ± 14.099 | -21.06 ± 11.086 |
| mmol/L | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) |
|---|---|---|---|---|
| MP Baseline S-K level | 4.55 ± 0.427 | 4.51 ± 0.357 | 4.38 ± 0.407 | 4.45 ± 0.372 |
| MP Study Day 2 Mean change | 0.13 ± 0.411 | -0.01 ± 0.372 | -0.04 ± 0.384 | -0.02 ± 0.400 |
| MP Study Day 8 Mean change | 0.50 ± 0.538 | 0.30 ± 0.467 | 0.12 ± 0.523 | -0.10 ± 0.535 |
| MP Study Day 12 Mean change | 0.60 ± 0.580 | 0.26 ± 0.541 | 0.10 ± 0.594 | -0.11 ± 0.572 |
| MP Study Day 15 Mean change | 0.54 ± 0.694 | 0.25 ± 0.535 | 0.11 ± 0.552 | -0.10 ± 0.546 |
| MP Study Day 19 Mean change | 0.55 ± 0.672 | 0.22 ± 0.580 | 0.17 ± 0.483 | 0.01 ± 0.605 |
| MP Study Day 22 Mean change | 0.55 ± 0.627 | 0.30 ± 0.563 | 0.27 ± 0.650 | 0.03 ± 0.579 |
| MP Study Day 26 Mean change | 0.55 ± 0.623 | 0.34 ± 0.565 | 0.33 ± 0.673 | 0.05 ± 0.594 |
| MP Study Day 29 Mean change | 0.52 ± 0.545 | 0.28 ± 0.664 | 0.14 ± 0.668 | -0.04 ± 0.554 |
| MP Study Day 29/Exit Mean change | 0.56 ± 0.582 | 0.25 ± 0.645 | 0.11 ± 0.768 | -0.09 ± 0.598 |
| Percent Change | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) |
|---|---|---|---|---|
| MP Study Day 2 Percent change | 3.39 ± 9.044 | 0.06 ± 8.036 | -0.51 ± 8.862 | -0.20 ± 8.984 |
| MP Study Day 8 Percent change | 11.64 ± 12.291 | 6.93 ± 10.486 | 3.05 ± 12.346 | -1.74 ± 12.043 |
| MP Study Day 12 Percent change | 13.70 ± 13.072 | 6.38 ± 12.287 | 2.85 ± 13.595 | -2.00 ± 12.836 |
| MP Study Day 15 Percent change | 12.51 ± 15.693 | 5.95 ± 12.169 | 2.93 ± 12.662 | -1.89 ± 12.118 |
| MP Study Day 19 Percent change | 12.96 ± 15.791 | 5.33 ± 12.934 | 4.28 ± 11.231 | .095 ± 13.697 |
| MP Study Day 22 Percent change | 12.84 ± 14.342 | 6.98 ± 12.774 | 6.79 ± 15.174 | 1.39 ± 12.782 |
| MP Study Day 26 Percent change | 13.03 ± 14.566 | 7.98 ± 12.932 | 8.08 ± 15.516 | 1.88 ± 16.641 |
| MP Study Day 29 Percent change | 12.09 ± 13.116 | 6.12 ± 14.424 | 3.02 ± 17.785 | -1.43 ± 13.664 |
| MP Study Day 29/Exit Percent change | 12.97 ± 13.116 | 6.12 ± 14.424 | 3.02 ± 17.785 | -1.43 ± 13.664 |
| Days | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) |
|---|---|---|---|---|
| Median Time to Hyperkalemia (S-K ≥ 5.1mmol/L) | 7 (6 to 7) | 14 (7 to 28) | NA (NA to NA) | NA (NA to NA) |
| mmol/L | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) |
|---|---|---|---|---|
| Mean S-K Intra-subject Standard Deviation Calculated Among Subjects With ≥ 2 Values on or After Maintenance Phase Study Day 8 | 0.06392 (0.05804 to 0.06980) | 0.06367 (0.05574 to 0.07159) | 0.07708 (0.06941 to 0.08474) | 0.06849 (0.06126 to 0.07571) |
| Proportion of subjects | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) |
|---|---|---|---|---|
| Baseline | 0.866 | 0.933 | 0.920 | 0.926 |
| MP Study Day 2 | 0.84 | 0.933 | 0.918 | 0.944 |
| MP Study Day 8 | 0.481 | 0.711 | 0.820 | 0.852 |
| MP Study Day 12 | 0.400 | 0.750 | 0.787 | 0.849 |
| MP Study Day 15 | 0.438 | 0.705 | 0.851 | 0.827 |
| MP Study Day 19 | 0.449 | 0.744 | 0.787 | 0.882 |
| MP Study Day 22 | 0.442 | 0.674 | 0.667 | 0.882 |
| MP Study Day 26 | 0.486 | 0.738 | 0.711 | 0.843 |
| MP Study Day 29 | 0.507 | 0.667 | 0.816 | 0.907 |
| MP Study Day 29/Exit | 0.476 | 0.711 | 0.760 | 0.852 |
Median time to relapse in S-K values (return to original Acute Phase S-K baseline value)
| Days | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) |
|---|---|---|---|---|
| Median Time to Relapse in S-K Values | 19 (12 to 28) | 29 (29 to NA) | NA (NA to NA) | NA (NA to NA) |
| log(mmol/L/hour) | Acute Phase: ZS 10 g TID |
|---|---|
| 24 hours after start of ZS dosing | -0.00373 ± 0.000231 |
| 48 hours of start of ZS dosing | -0.00324 ± 0.000130 |
| mmol/L | Acute Phase: ZS 10 g TID |
|---|---|
| Acute phase baseline | 5.55 ± 0.449 |
| 1 hour after start of ZS dosing Mean change | -0.23 ± 0.435 |
| 2 hours after start of ZS dosing Mean change | -0.41 ± 0.440 |
| 4 hours after start of ZS dosing Mean change | -0.51 ± 0.405 |
| 24 hours after start of ZS dosing Mean change | -0.68 ± 0.448 |
| 1 hour after 1st dose Study Day 2 Mean change | -0.75 ± 0.444 |
| 48 hours after start of ZS dosing Mean change | -1.05 ± 0.510 |
| Percent Change | Acute Phase: ZS 10 g TID |
|---|---|
| 1 hour after start of ZS dosing Percent change | -3.91 ± 7.741 |
| 2 hours after start of ZS dosing Percent change | -7.13 ± 7.706 |
| 4 hours after start of ZS dosing Percent change | -9.00 ± 7.123 |
| 24 hours after start of ZS dosing Percent change | -12.03 ± 7.808 |
| 1 hour after 1st dose Study Day 2 Percent change | -13.41 ± 7.720 |
| 48 hours after start of ZS dosing Percent change | -18.56 ± 8.506 |
| Proportion of subjects | Acute Phase: ZS 10 g TID |
|---|---|
| 24 hours after start of dosing | 0.661 |
| 48 hours after of start dosing | 0.88 |
| Hours | Acute Phase: ZS 10 g TID |
|---|---|
| Median Time to Normalization (3.50-5.0 mmol/L) in S-K Levels in the 48 Hours of Initial Treatment | 2.17 (2 to 3.97) |
Collected over All adverse events were collected beginning with the first administration of study drug and through end of study treatment follow up visit. End of treatment study follow up visit was 7 days +/- 1 day after last dose of investigational product.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZS 10 g TID (Acute Phase) | — | 0/258 (0%) | 9/258 (3.5%) |
| Placebo Comparator (Maintenance Phase) | — | 0/85 (0%) | 25/85 (29.4%) |
| ZS 5 g Once Daily (Maintenance Phase) | — | 5/45 (11.1%) | 20/45 (44.4%) |
| ZS 10 g Once Daily (Maintenance Phase) | — | 2/51 (3.9%) | 15/51 (29.4%) |
| ZS 15 g Once Daily (Maintenance Phase) | — | 3/56 (5.4%) | 25/56 (44.6%) |
| Event | ZS 10 g TID (Acute Phase) | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) |
|---|---|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/258 | 0/85 | 1/45 | 0/51 | 0/56 |
| Small intestinal obstructionGastrointestinal disorders | 0/258 | 0/85 | 1/45 | 0/51 | 0/56 |
| HepatotoxicityHepatobiliary disorders | 0/258 | 0/85 | 1/45 | 0/51 | 0/56 |
| PneumoniaInfections and infestations | 0/258 | 0/85 | 1/45 | 0/51 | 1/56 |
| Confusional statePsychiatric disorders | 0/258 | 0/85 | 1/45 | 0/51 | 0/56 |
| Myocardial infarctionCardiac disorders | 0/258 | 0/85 | 0/45 | 1/51 | 0/56 |
| CellulitisInfections and infestations | 0/258 | 0/85 | 0/45 | 1/51 | 0/56 |
| Generalized edemaGeneral disorders | 0/258 | 0/85 | 0/45 | 0/51 | 1/56 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/258 | 0/85 | 0/45 | 0/51 | 1/56 |
| Event | ZS 10 g TID (Acute Phase) | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) |
|---|---|---|---|---|---|
| EdemaGeneral disorders | 0/258 | 2/85 | 1/45 | 3/51 | 8/56 |
| FatigueGeneral disorders | 0/258 | 0/85 | 0/45 | 5/51 | 6/56 |
| Oedema peripheralGeneral disorders | 0/258 | 2/85 | 0/45 | 3/51 | 6/56 |
| ConstipationGastrointestinal disorders | 2/258 | 6/85 | 0/45 | 1/51 | 1/56 |
| Upper respiratory infectionInfections and infestations | 1/258 | 1/85 | 3/45 | 1/51 | 1/56 |
| AnemiaBlood and lymphatic system disorders | 0/258 | 0/85 | 0/45 | 0/51 | 3/56 |
| NasopharyngitisInfections and infestations | 0/258 | 1/85 | 0/45 | 0/51 | 3/56 |
| DyspepsiaGastrointestinal disorders | 0/258 | 0/85 | 2/45 | 0/51 | 0/56 |
| HypertensionVascular disorders | 0/258 | 1/85 | 2/45 | 1/51 | 2/56 |
| Renal failureRenal and urinary disorders | 0/258 | 0/85 | 2/45 | 0/51 | 0/56 |
Some participants contributed to more than one baseline group. 258 participants entered the acute phase; 251 completed the acute phase. Of these 251 participants, 240 were eligible for the maintenance phase. Three participants did not enter the maintenance phase; 237 participants were randomized for the maintenance phase.
| Age, Continuous(Years) | ZS 10 g Three Times Daily (Acute Phase) | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) | Total |
|---|---|---|---|---|---|---|
| Acute Phase | 64.0 ± 12.72 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 64.0 ± 12.72 |
| Maintenance Phase | NA ± NA | 64.3 ± 12.13 | 61.5 ± 16.89 | 63.8 ± 9.97 | 64.9 ± 12.85 | 63.80 ± 13.01 |
| Sex/Gender, Customized(Participants) | ZS 10 g Three Times Daily (Acute Phase) | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) | Total |
|---|---|---|---|---|---|---|
| Female, Acute Phase | 109 | 0 | 0 | 0 | 0 | 109 |
| Male, Acute Phase | 149 | 0 | 0 | 0 | 0 | 149 |
| Female, Maintenance Phase | 0 | 41 | 18 | 24 | 16 | 99 |
| Male, Maintenance Phase | 0 | 44 | 27 | 27 | 40 | 138 |
| Race/Ethnicity, Customized(Participants) | ZS 10 g Three Times Daily (Acute Phase) | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) | Total |
|---|---|---|---|---|---|---|
| White, Acute Phase | 215 | 0 | 0 | 0 | 0 | 215 |
| Black or African American, Acute Phase | 37 | 0 | 0 | 0 | 0 | 37 |
| Asian, Acute Phase | 5 | 0 | 0 | 0 | 0 | 5 |
| Native Hawaiian or other Pacific Islander, AP | 1 | 0 | 0 | 0 | 0 | 1 |
| Other, Acute Phase | 2 | 0 | 0 | 0 | 0 | 2 |
| Multiple Races indicated, Acute Phase | 1 | 0 | 0 | 0 | 0 | 1 |
| White, Maintenance Phase | 0 | 73 | 36 | 44 | 46 | 199 |
| Black or African American, Maintenance Phase | 0 | 10 | 8 | 5 | 9 | 32 |
| Asian, Maintenance Phase | 0 | 3 | 0 | 1 | 1 | 5 |
| Native Hawaiian or other Pacific Islander, MP | 0 | 1 | 0 | 0 | 0 | 1 |
| Other, Maintenance Phase | 0 | 0 | 1 | 1 | 0 | 2 |
| Multiple Races indicated, Maintenance Phase | 0 | 1 | 0 | 0 | 0 | 1 |
| Baseline Serum potassium ( S-K ) levels during both the Acute and Maintenance phases(Participants) | ZS 10 g Three Times Daily (Acute Phase) | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) | Total |
|---|---|---|---|---|---|---|
| <5.5 mmol/L, Acute Phase | 119 | 0 | 0 | 0 | 0 | 119 |
| 5.5-<6.0 mmol/L, Acute Phase | 100 | 0 | 0 | 0 | 0 | 100 |
| ≥ 6.0 mmol/L, Acute Phase | 39 | 0 | 0 | 0 | 0 | 39 |
| <5.5 mmol/L, Maintenance Phase | 0 | 43 | 23 | 19 | 24 | 109 |
| 5.5-<6.0 mmol/L, Maintenance Phase | 0 | 30 | 17 | 23 | 26 | 96 |
| ≥ 6.0 mmol/L, Maintenance Phase | 0 | 12 | 5 | 9 | 6 | 32 |
| eGFR at baseline during both the Acute and Maintenance phases(Participants) | ZS 10 g Three Times Daily (Acute Phase) | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) | Total |
|---|---|---|---|---|---|---|
| <60 mL/min, Acute Phase | 179 | 0 | 0 | 0 | 0 | 179 |
| ≥ 60 mL/min, Acute Phase | 72 | 0 | 0 | 0 | 0 | 72 |
| Not reported, Acute Phase | 7 | 0 | 0 | 0 | 0 | 7 |
| <60 mL/min, Maintenance Phase | 0 | 52 | 31 | 38 | 41 | 162 |
| ≥ 60 mL/min, Maintenance Phase | 0 | 28 | 12 | 13 | 15 | 68 |
| Not reported, Maintenance Phase | 0 | 5 | 2 | 0 | 0 | 7 |
| Etiology of elevated S-K levels during both the Acute and Maintenance phases(Participants) | ZS 10 g Three Times Daily (Acute Phase) | Placebo Comparator (Maintenance Phase) | ZS 5 g Once Daily (Maintenance Phase) | ZS 10 g Once Daily (Maintenance Phase) | ZS 15 g Once Daily (Maintenance Phase) | Total |
|---|---|---|---|---|---|---|
| RAAS inhibitor medication, Acute Phase | 180 | 0 | 0 | 0 | 0 | 180 |
| Diabetes mellitus, Acute Phase | 170 | 0 | 0 | 0 | 0 | 170 |
| Chronic kidney disease, Acute Phase | 169 | 0 | 0 | 0 | 0 | 169 |
| Heart failure, Acute Phase | 94 | 0 | 0 | 0 | 0 | 94 |
| RAAS inhibitor medication, Maintenance Phase | 0 | 61 | 33 | 36 | 33 | 163 |
| Diabetes mellitus, Maintenance Phase | 0 | 54 | 26 | 38 | 39 | 157 |
| Chronic kidney disease, Maintenance Phase | 0 | 50 | 29 | 36 | 37 | 152 |
| Heart failure, Maintenance Phase | 0 | 26 | 18 | 18 | 25 | 87 |
Ran from Mar 2014 to primary completion in Aug 2014, 5 months.
Results were first posted in Dec 2018, 4 years 3 months after primary completion. A results delay was requested in Aug 2014.
Of 18 phase 3 interventional studies under Hyperkalemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium zirconium cyclosilicate